Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MYC | P01106 | 1/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.32 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.32 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.32 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.32 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.31 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.31 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.31 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.31 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.30 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.30 |
| ▸ | GSK3B | P49841 | 1/20 | 0.30 |
| ▸ | CSNK1G2 | P78368 | 1/20 | 0.30 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.30 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12575857 | 0.99 | SCN9A (0.32) | MYCGABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL12575714 | 0.98 | MYC (0.33) | MYCGABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL10010543 | 0.97 | ABCG2 (0.33) | MYCGABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL12575844 | 0.94 | PGR (0.32) | — | |
| SCHEMBL12575723 | 0.93 | ABCG2 (0.32) | MYCABCG2CSNK1A1CSNK1DGSK3B | |
| SCHEMBL12575717 | 0.93 | PTGDR2 (0.38) | MYCPTGDR2ABCG2 | |
| SCHEMBL12575683 | 0.93 | PTGDR2 (0.38) | MYCPTGDR2ABCG2 | |
| SCHEMBL12575598 | 0.93 | ABCG2 (0.32) | MYCABCG2CSNK1A1CSNK1DGSK3B | |
| SCHEMBL10353959 | 0.92 | ABCG2 (0.35) | MYCGABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL12575708 | 0.92 | PTGDR2 (0.31) | MYCPTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9126892-B2 | Blue fluorescence compound and organic electroluminescence device using the same | LG DISPLAY CO., LTD. (KR) | 2015-09-08 | — | — | US | disclosed |
| US-20110156011-A1 | BLUE FLUORESCENCE COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE USING THE SAME | LG DISPLAY CO., LTD. (KR) | 2011-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110156011-A1 | BLUE FLUORESCENCE COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE USING THE SAME | KCNN2, ORAI2, ETV6 | MYC 182/4885GABRA1 1933/4885GABRG2 2824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.